

This listing of the claims will replace all prior listings and versions of claims in the application:

1-60. (CANCELLED).

61. An isolated or purified polypeptide comprising the amino acid sequence shown in SEQ ID NO:2.

62-71. (CANCELLED)

72. (CURRENTLY AMENDED) A composition comprising a polypeptide of claim 61~~any of claims 61 to 71~~ and a carrier.

73. The composition of claim 72, wherein the carrier is selected from the group consisting of an adjuvant, a solid support, a stabilizer, a preservative and a pharmaceutically acceptable carrier.

74-75. (CANCELLED)

76. (CURRENTLY AMENDED) An isolated polypeptide of claim 61~~any of claims 61, 74 or 75~~, which has been recombinantly produced and isolated from a cell.

77. (CURRENTLY AMENDED) A process for chemically synthesizing a polypeptide, which comprises providing the amino acid sequence of the polypeptide of claim 61~~any of claims 61, 74 or 75~~, and chemically linking the amino acids in an orientation and under suitable conditions so as to produce the polypeptide.

78. (CURRENTLY AMENDED) A method of screening for an agent that inhibits the binding of a polypeptide of claim 61~~any of claims 61 or 74~~, to a Fas receptor, the method comprising:

- a) providing a Fas receptor cytoplasmic domain bound to a solid support;
- b) contacting the agent to be tested with the solid support of step a) under conditions favoring binding of said cytoplasmic domain to said polypeptide;

c) contacting the polypeptide that has been detectable-labeled to the solid support of step b) under conditions favoring binding the cytoplasmic domain to the polypeptide;

d) detecting the presence of complex formation between the cytoplasmic domain and the polypeptide; the absence of complex formation indicating that the agent inhibits the binding of the polypeptide to the cytoplasmic domain of the Fas receptor.